Healthy VolunteersEarly Phase 1NCT05995119
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
A Early Phase 1 study testing Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) in people with Healthy Volunteers and Fasting, run by TAHO Pharmaceuticals Ltd. at 1 site in United States.
Trial summary
The goal of this clinical trial is to evaluate the pharmacokinetic profiles and bioequivalence, and to determine the safety and tolerability of the TAH3311 Oral Dissolving Film (ODF) 5mg compared with ELIQUIS® (Apixaban) 5mg Oral Tablet, after single dose under fasted and fed conditions in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers, Fasting, Fed
- What is being tested?
- Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Dec 2022to 13 Jan 2023
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and non-pregnant, non-lactating females, 18-80 years of age, inclusive.
- A minimum body weight of 60 kg and a Body Mass Index (BMI) of 18.5-29.9 kg/m², inclusive. BMI will be calculated using Novum Pharmaceutical Research Services Standard Operating Procedures.
- Female subjects must meet at least one of the following requirements:
- Agree to abstain from sexual intercourse from screening and throughout the duration of the study, including washout periods, and for 30 days after the last study drug administration.
- Have used and agree to continue to use a reliable method of hormonal contraception (oral, implanted, or injected) in conjunction with a barrier method (e.g., diaphragm, cervical cap, male condom, and female condom and spermicidal foam, sponges, and film) for at least 30 days before initial dosing and throughout the duration of the study, including washout periods, and for 30 days after the last study drug administration.
- Have used and agree to continue to use an intrauterine device (IUD) at least 3 months before initial dosing and throughout the duration of the study, including washout periods, and for 30 days after the last study drug administration.
Show all 12Show fewer
- Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation at least 3 months before initial dosing or Essure® device placement before the year 2018).
- At least 2 years postmenopausal and have a documented follicle stimulating hormone (FSH) level ≥ 40 milli-international units per milliliter (mIU/mL) at screening.
- Male subjects who are not surgically sterile must agree to abstain from sexual intercourse (complete abstinence) or use appropriate contraceptive measures and agree to not impregnate a female partner(s) and not to donate sperm throughout the entire study, including the washout periods, and for 30 days after the last study drug administration. Examples of acceptable methods of contraception include a double-barrier method of contraception (e.g., condom with spermicide). Other forms of contraception may be acceptable, at the discretion of the Investigator.
- Subject is judged by an Investigator to be in good health as determined by lack of clinically significant abnormalities in health assessments performed at screening. Any abnormalities or deviations outside the normal ranges for any clinical testing (e.g., laboratory tests, ECG, vital signs) may be repeated, at the discretion of the Investigator(s), and judged by an Investigator to be not clinically significant for study participation.
- Subject doesn't have any relevant dietary restrictions, as determined by the Investigator, and is willing to consume a high-fat, high-calorie breakfast and other standard meals provided during the treatment periods of the study, and to comply with the fasting conditions required by the study design.
- Subject is able to read and speak English fluently. Subjects will be required to read, understand, sign and date the informed consent form, which meets all criteria of current FDA regulations, and must be able to understand the information and instruction given to them during the study.
Who cannot join
- Females who are pregnant, lactating, or likely to become pregnant during the study.
- History of allergy or sensitivity to apixaban, or history of any food or drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
- Current tongue piercing or other piercings in the mouth, including lips and cheeks which have studs/rings, etc. or where the piercing wound is not completely closed or any tongue or other oral deformities that may affect the absorption of the drug product.
- Significant history or current evidence of system disorders, organ dysfunction especially cardiovascular disorders (e.g., atrial fibrillation), renal or hepatic disorders.
- Significant familial history of sudden cardiac death, as determined by the Investigator.
- Subject has a prosthetic heart valve.
Show all 29Show fewer
- Significant history or current evidence of blood clots or bleeding disorders (e.g., bleeding diathesis [tendency to bleed or bruise easily]), stroke, or active pathological bleeding.
- Clinically significant history or are currently at risk for arterial or venous thromboembolic events (e.g., transient ischemic attack, cerebrovascular accident, myocardial infarction, retinal artery occlusion or retinal vein thrombosis, pulmonary embolism, deep vein thrombosis, antiphospholipid syndrome), as determined by the Investigator.
- Serum creatinine ≥ 1.5 mg/dL.
- Creatinine clearance (CrCl) < 50 mL/min; obtained from the clinical laboratory tests performed at screening. CrCl can be estimated using the following (Cockcroft-Gault) equation:
- CrCl= ((140-age) × actual weight(kg) × [0.85 if female])/(SerumCr(mg⁄dL) × 72)
- Clinically significant history or presence of gastrointestinal disease (e.g., bleeding, perforation, or fistulas) or malabsorption, as determined by the Investigator.
- Subject has had an acute infection within 2 weeks before screening or at any time between screening and check-in including, but not limited to, history, signs, or symptoms of a common cold (e.g., mild rhinorrhea), untreated oral/dental abnormalities (e.g., untreated dental caries as determined by examination of the mouth), or untreated disruption of the skin, as determined by the Investigator.
- Subject has an active infection requiring systemic therapy at the time of screening, which is considered clinically significant by the Investigator.
- Subject has a significant history of or ongoing chronic or recurrent infectious disease (e.g., infected indwelling prosthesis, osteomyelitis, chronic sinusitis), as determined by the Investigator.
- Anticipating undergoing surgery or medical/dental procedure, receiving neuraxial anesthesia (spinal/epidural anesthesia), or undergoing spinal puncture during the study or within 7 days after study completion.
- History of psychiatric disorders occurring within the last two years, which required the subject to be hospitalized or treated with medication.
- Presence of a medical condition requiring regular treatment with prescription drugs (except hormonal contraceptives).
- Use of pharmacologic agents or herbal products known to significantly induce or inhibit drug-metabolizing enzymes (especially inhibitors and inducers of CYP3A4 and P-gp such as ketoconazole, itraconazole, ritonavir, clarithromycin, rifampin, phenytoin, carbamazepine, St. John's Wort, etc.) within 30 days before initial dosing.
- Use of drugs affecting hemostasis such as aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and nonsteroidal anti-inflammatory drugs (NSAIDs) within 14 days before initial dosing.
- Receipt of any drug as part of a research study within 30 days before initial dosing.
- Drug or alcohol addiction requiring treatment in the 12 months before initial dosing.
- History of excessive alcohol consumption (on average more than 14 units of alcohol/week; 1 unit = 12 oz. beer, 6 oz. wine, 1 shot [1.5 oz.] of liquor) during the past 12 months.
- Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing.
- Positive test for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
- Positive test results for drugs of abuse or cotinine at screening.
- If female, has a positive pregnancy test at screening.
- Difficulty swallowing, as determined by the Investigator.
- Use of tobacco- or nicotine-containing products within 1 year before initial dosing.
Trial locations and contacts
1 site in 1 country.
United States1 site
Novum Pharmaceutical Research Services
Las Vegas, Nevada, 89121
About this study
Official title: A Phase I, Randomized, Single-Dose, Open-Label, Four-Way Crossover Study to Evaluate the Comparative Bioavailability of Apixaban for TAH3311 Oral Dissolving Film Versus ELIQUIS® Oral Tablet in Healthy Male and Female Subjects
The goal of this clinical trial is to evaluate the pharmacokinetic profiles and bioequivalence, and to determine the safety and tolerability of the TAH3311 Oral Dissolving Film (ODF) 5mg compared with ELIQUIS® (Apixaban) 5mg Oral Tablet, after single dose under fasted and fed conditions in healthy volunteers.
Read the detailed description
For Treatment T1, the test product was administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. For Treatment T2, the test product was administered orally following an overnight fast of at least 10 hours.
The test treatment (1 × TAH3311 (apixaban) oral dissolving film 5 mg) was placed on the top of the tongue. Subjects were asked to close their mouth naturally and not to swallow for at least 60 seconds or until they felt that the film had fully dissolved. They were asked to indicate this to the dosing staff by raising their hand, who then verified. If any film remained in the mouth, after the subject raised his/her hand, the subject was reminded to not swallow and requested to close their mouth and allow the film to continue to dissolve and the study staff monitored the subject's mouth every 1 minute until such time that the film had fully dissolved. The time taken from dosing until the film had completely dissolved was documented. Dosing time was considered the time when the film was placed on the subject's tongue.
No water was administered with the Test Treatments (T1 and T2).
Reference Treatments (R1 \& R2):
For Treatment R1, the reference product was administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. For Treatment R2, the reference product was administered orally following an overnight fast of at least 10 hours.
Each dose was administered with 240 mL of room temperature water. Subjects were instructed to swallow the tablet whole without chewing or biting. Any subject, who bit or chewed the tablet, was dropped from the study. Immediately after dosing a mouth check was performed to ensure that the tablet was swallowed whole without chewing or biting.
- Conditions
- Healthy Volunteers, Fasting, Fed
- Being tested
- Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
- Medical subject headings
- Fasting, Lecithin Cholesterol Acyltransferase Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)Drug
Also called TAH3311 5 mg ODF
The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
| Study group | Role | What they receive |
|---|---|---|
| Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fed conditions | Other | Not described Receives: Drug: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) |
| Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fast conditions | Other | Not described Receives: Drug: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma Concentration (Cmax) of Apixaban under fasted condition
Measured: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Area under the plasma concentration curve from time zero to last sampling time (AUC0-t) of Apixaban under fasted condition
Measured: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Area under the plasma concentration curve from time zero to infinity (AUC0-∞) of Apixaban under fasted condition
Measured: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2023
- Study start5 Dec 2022
- Primary completion28 Dec 2022
- Study completion13 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- TAHO Pharmaceuticals Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Philip Mathew, M.D., Principal investigator, Novum Pharmaceutical Research Services, USA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05995119
- Sponsor's protocol ID
- TAH3311-12288201
- Status last verified
- Aug 2023
- First submitted
- 24 Jul 2023
- Last updated
- 18 Aug 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Randomized, Single-Dose, Open-Label, Four-Way Crossover Study to Evaluate the Comparative Bioavailability of Apixaban for TAH3311 Oral Dissolving Film Versus ELIQUIS® Oral Tablet in Healthy Male and Female Subjects
- ClinicalTrials.gov ID
- NCT05995119
- Acronym / sponsor ID
- TAH3311-12288201
- Conditions
- Healthy Volunteers, Fasting, Fed
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- TAHO Pharmaceuticals Ltd.Industry (pharma, biotech, devices)
- Study start
- 5 Dec 2022 (actual)
- Primary completion
- 28 Dec 2022 (actual)
- Study completion
- 13 Jan 2023 (actual)
- First posted
- 16 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the pharmacokinetic profiles and bioequivalence, and to determine the safety and tolerability of the TAH3311 Oral Dissolving Film (ODF) 5mg compared with ELIQUIS® (Apixaban) 5mg Oral Tablet, after single dose under fasted and fed conditions in healthy volunteers.
Detailed description
For Treatment T1, the test product was administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. For Treatment T2, the test product was administered orally following an overnight fast of at least 10 hours.
The test treatment (1 × TAH3311 (apixaban) oral dissolving film 5 mg) was placed on the top of the tongue. Subjects were asked to close their mouth naturally and not to swallow for at least 60 seconds or until they felt that the film had fully dissolved. They were asked to indicate this to the dosing staff by raising their hand, who then verified. If any film remained in the mouth, after the subject raised his/her hand, the subject was reminded to not swallow and requested to close their mouth and allow the film to continue to dissolve and the study staff monitored the subject's mouth every 1 minute until such time that the film had fully dissolved. The time taken from dosing until the film had completely dissolved was documented. Dosing time was considered the time when the film was placed on the subject's tongue.
No water was administered with the Test Treatments (T1 and T2).
Reference Treatments (R1 \& R2):
For Treatment R1, the reference product was administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. For Treatment R2, the reference product was administered orally following an overnight fast of at least 10 hours.
Each dose was administered with 240 mL of room temperature water. Subjects were instructed to swallow the tablet whole without chewing or biting. Any subject, who bit or chewed the tablet, was dropped from the study. Immediately after dosing a mouth check was performed to ensure that the tablet was swallowed whole without chewing or biting.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fed conditions | Other | Drug: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) |
| Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fast conditions | Other | Drug: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Males and non-pregnant, non-lactating females, 18-80 years of age, inclusive.
- A minimum body weight of 60 kg and a Body Mass Index (BMI) of 18.5-29.9 kg/m², inclusive. BMI will be calculated using Novum Pharmaceutical Research Services Standard Operating Procedures.
- Female subjects must meet at least one of the following requirements:
- Male subjects who are not surgically sterile must agree to abstain from sexual intercourse (complete abstinence) or use appropriate contraceptive measures and agree to not impregnate a female partner(s) and not to donate sperm throughout the entire study, including the washout periods, and for 30 days after the last study drug administration. Examples of acceptable methods of contraception include a double-barrier method of contraception (e.g., condom with spermicide). Other forms of contraception may be acceptable, at the discretion of the Investigator.
- Subject is judged by an Investigator to be in good health as determined by lack of clinically significant abnormalities in health assessments performed at screening. Any abnormalities or deviations outside the normal ranges for any clinical testing (e.g., laboratory tests, ECG, vital signs) may be repeated, at the discretion of the Investigator(s), and judged by an Investigator to be not clinically significant for study participation.
Key exclusion criteria (29 listed)
- Females who are pregnant, lactating, or likely to become pregnant during the study.
- History of allergy or sensitivity to apixaban, or history of any food or drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
- Current tongue piercing or other piercings in the mouth, including lips and cheeks which have studs/rings, etc. or where the piercing wound is not completely closed or any tongue or other oral deformities that may affect the absorption of the drug product.
- Significant history or current evidence of system disorders, organ dysfunction especially cardiovascular disorders (e.g., atrial fibrillation), renal or hepatic disorders.
- Significant familial history of sudden cardiac death, as determined by the Investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)Also: TAH3311 5 mg ODFThe subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods. | Drug | Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fast conditions, Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fed conditions |
Primary outcome
Plasma Concentration (Cmax) of Apixaban under fasted condition
Time frame: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Area under the plasma concentration curve from time zero to last sampling time (AUC0-t) of Apixaban under fasted condition
Time frame: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Area under the plasma concentration curve from time zero to infinity (AUC0-∞) of Apixaban under fasted condition
Time frame: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2023.
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip Mathew, M.D. principal investigator
Novum Pharmaceutical Research Services, USA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) in people with Healthy Volunteers and Fasting, run by TAHO Pharmaceuticals Ltd. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma Concentration (Cmax) of Apixaban under fasted condition (time frame: 0, 0.33, 0.67, 1.0, 1.5, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 hours post dose). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2023.